Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.
GLOBETECH PUBLISHING

Spinal Fluid Marker Strongly Predicts Mental Decline

By Labmedica International staff writers
Posted on 19 Mar 2012
A novel marker of Alzheimer's disease (AD) can predict how rapidly a patient's memory and other mental abilities will decline after the disorder is diagnosed.

Higher levels of the marker, visinin-like protein 1 (VILIP-1), in the cerebrospinal fluid (CSF) of Alzheimer's patients have been linked to a more rapid mental decline in the years that followed.

Scientists at Washington University School of Medicine (St. Louis, MO, USA) studied 60 individuals with a clinical diagnosis of very mild or mild AD and measuring baseline CSF protein levels of VILIP-1, Tau, phosphorylated Tau-181 (p-tau181), and amyloid-beta 1–42 (Aβ42), and these were followed longitudinally for an average of 2.6 years.

Baseline CSF VILIP-1 and VILIP-1/Aβ42 levels predicted rates of future decline in the clinical dementia rating and global composite scores over the follow-up period. Individuals with CSF VILIP-1 equal to or greater than 560 pg/mL progressed much more rapidly than individuals with lower values. CSF tau, p-tau181, tau/ Aβ42, and p-tau181/ Aβ42 also predicted more rapid cognitive decline overtime. Scientists think VILIP-1 serves as a calcium sensor in brain cells. It is released into the cerebrospinal fluid when the cells are injured. CSF samples were analyzed for total tau, p-tau181, Aβ42 using Innotest, (Innogenetics, Ghent, Belgium), and CSF Aβ40 by an enzyme-linked immunosorbent assay. CSF samples were analyzed for VILIP-1 by Erenna, a microparticle-based immunoassay (Singulex, CA, USA).

Rawan Tarawneh, MD, the lead author of the study, said "VILIP-1 appears to be a strong indicator of ongoing injury to brain cells as a result of Alzheimer's disease. That could be very useful in predicting the course of the disease and in evaluating new treatments in clinical trials. These results are intriguing, but we need a larger study to fully understand how the insights provided by VILIP-1 compare to those we can gain from other markers.” The study was published online on February 22, 2012, in the journal Neurology.

Related Links:
Washington University School of Medicine
Innogenetics
Singulex



EUROIMMUN AG
PURITAN MEDICAL
Sekisui Diagnostics
comments powered by Disqus
Life Technologies

Channels

Pathology

view channel

New Approach Identifies Multiple Melanoma Drug Resistance Biomarkers

A recent paper described the use of liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM) for assessing melanoma biomarkers in the blood in order to determine the effectiveness of chemotherapy. Modern chemotherapeutic techniques based on treatment with multiple anticancer drugs require the identification... Read more

Lab Technology

view channel

The Prostatome – a Novel Prostate Atlas Combining Anatomic and Disease Pathology Data Founded

Scientists have succeeded in fusing prostate cancer pathology data with anatomical magnetic resonance imaging (MRI) data to create the foundation of a first-of-its-kind prostate atlas for prostate cancer. A team of scientists and clinicians, led by Anant Madabhushi, professor of biomedical engineering and director of... Read more

Industry News

view channel

IDT Acquires SURVEYOR Nuclease Product Line from Transgenomic

The SURVEYOR line is to be used by Integrated DNA Technologies (IDT; Coralville, IA, USA) primarily to support researchers performing mutation detection and potentially-clinical genome editing, and by Transgenomic, Inc. (Omaha, NE, USA) primarily to support diagnostic and other clinical applications. IDT, a world leader... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.